Skip to main content
Toggle navigation
Login
Search
Home
Conference Program
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
G
Gadkar, Kapil
Genentech
(
W-035
)
Systems model to predict fractional exhaled nitric oxide response to inhaled JAK inhibitors in patients with mild to moderate asthma
Kapil Gadkar
Favorite
Gaffney, Anna
Certara USA, Inc., Radnor, PA
(
M-034
)
Population Pharmacokinetic Modeling of Niraparib to Assess Different Absorption Models
Anna Gaffney
Favorite
Gallais, Fanny
Pharmetheus AB
(
T-041
)
Bimekizumab population pharmacokinetic and exposure-response analyses in adults with moderate to severe hidradenitis suppurativa
Fanny Gallais
Favorite
Gao, Xizhe
Pfizer Inc
(
W-070
)
Concentration-QTc Analysis of PF-07220060 in Patients with Advanced Solid Tumors
Xizhe Gao
Favorite
Gastonguay, Marc
Metrum Research Group
(
M-036
)
Pharmacometric-Pharmacoeconomic Modeling and Simulation in Atopic Dermatitis: Informing Early Drug Development Decisions for a Hypothetical New Therapeutic
Marc Gastonguay
Favorite
Gaudreault, Francois
Vigil Neuroscience, Inc
(
T-042
)
Use of Model-informed Drug Development and Natural History Data to Inform the Development of Iluzanebart in ALSP: A Neurological Rare Disease
Francois Gaudreault
Favorite
Gebhart, Anthony
University of Florida - Center for Pharmacometrics & Systems Pharmacology
(
T-043
)
Advancing Drug Development through Enhanced Exposure-Response Analysis: The R-Shiny App ERpmx
Anthony Gebhart
Favorite
Gharahi, Hamidreza
Takeda Pharmaceuticals
(
T-044
)
A translational quantitative systems pharmacology modeling framework for FcRn antagonist therapy for myasthenia gravis
Hamidreza Gharahi
Favorite
Ghasemi, Mohammad
Arcus Biosciences
(
W-036
)
Population Plasma and Urine Pharmacokinetic Data and Modelling of Casdatifan Supports Administration to Participants with Moderate Renal Impairment
Mohammad Ghasemi
Favorite
Gonzalez, Juan
Pumas-AI, Inc.
(
W-037
)
Evaluation of Large Language Models for an AI Chat Assistant Focused on Pumas and Pharmacometrics
Juan Gonzalez
Favorite
Goo, Sungwoo
Chungnam National University
(
T-045
)
Mixed effect state space model application for data driven pharmacometrics modeling
Sungwoo Goo
Favorite
Gordi, Toufigh
Rigel Pharmaceuticals
(
T-046
)
A Mixed-effect Pharmacokinetic Model of R835, a Novel Dual IRAK1/4, in Healthy Volunteers After Administration of the Prodrug R289
Toufigh Gordi
Favorite
Goryacheva, Ekaterina
InSysBio UK
(
T-047
)
FIVEDB as a tool for analysis of in vitro experimental data: cytokine production by primary cells and cell lines
Ekaterina Goryacheva
Favorite
Gosselin, Nathalie
Certara
(
M-037
)
K-PD model of Plozasiran in Patients with Severe Hypertriglyceridemia
Nathalie Gosselin
Favorite
(
M-038
)
K-PD Modeling of Plozasiran - Mixed Hyperlipidemia
Nathalie Gosselin
Favorite
Greenwald, Eric
Pfizer Inc
(
T-048
)
App-based in vitro pharmacokinetic driver identification and in silico clinical trial assessment of pharmacokinetic driver models
Eric Greenwald
Favorite
Grinshpun, Boris
Certara USA, Radnor, PA
(
T-049
)
Building Automated Pharmacometrics Analysis Workflows in R with NMsim
Boris Grinshpun
Favorite
Guimaraes, Mariana
ESQlabs GmbH
(
T-050
)
A review of OSP suite PBBM capabilities: looking ahead
Mariana Guimaraes
Favorite
Guo, Yang
Alexion Pharmaceuticals, Inc.
(
T-099
)
Acoramidis (ALXN2060) Population Pharmacokinetic Modeling and the Importance of Exploring Categorization of Covariate Values
Yang Guo
Favorite
Gupta, Kajal
University of Florida
(
M-039
)
A PBPK-QSP model for regulation of thyroid hormones in Allan-Herndon Dudley Syndrome
Kajal Gupta
Favorite
